Serum IgG and IgA antibodies specific for Chlamydia trachomatis in salpingitis patients as determined by the immunoperoxidase assay.
The feasibility of applying elevated Chlamydia trachomatis specific IgG antibody and serum IgA antibodies as a non-invasive screening test for C. trachomatis associated salpingitis was analysed in 54 salpingitis patients and 294 apparently healthy women by the single antigen (L2) immunoperoxidase assay (IPA). The prevalence rate of C. trachomatis IgG antibody (titre greater than or equal to 64) was significantly higher in the salpingitis patients in comparison to control (67% versus 23%). The prevalence rate of elevated C. trachomatis IgG titres (greater than or equal to 128, greater than or equal to 256 and greater than or equal to 512) was significantly higher in the salpingitis patients as compared to the controls. For example, at an IgG titre of greater than or equal to 128 the prevalence rate was 57% in the salpingitis patients and 8% in the healthy controls (p less than 0.0001). The prevalence of C. trachomatis IgA antibodies (titre greater than or equal to 16) was significantly higher in salpingitis patients in comparison to controls (37% versus 4%). The prevalence of elevated IgA titres (greater than or equal to 32 and greater than or equal to 64) was found to be significantly higher in salpingitis patients as compared to controls. All the IgG seropositive salpingitis patients were also found to have C. trachomatis IgG antibodies. It appears that testing for IgG antibodies at a serum dilution of 1:128, and for IgA antibodies at a dilution of 1:16 by the IPA test comprises the best combination for the differentiation between the salpingitis patients and apparently healthy controls, and it is suggested that this be used as a marker of active C. trachomatis infection.